Late-Onset Hypogonadism Syndrome and Lower Urinary Tract Symptoms by Shigehara, Kazuyoshi & Namiki, Mikio
Korean Journal of Urology
Ⓒ The Korean Urological Association, 2011 657 Korean J Urol 2011;52:657-663
www.kjurology.org
http://dx.doi.org/10.4111/kju.2011.52.10.657
Review Article
Late-Onset Hypogonadism Syndrome and Lower Urinary Tract 
Symptoms
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Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan
Androgen replacement therapy (ART) is a widely accepted form of treatment worldwide 
for aging men with late-onset hypogonadism (LOH) syndrome. Concurrent with the 
progressive decline in testosterone from middle age, there is a gradual increase in pros-
tate volume, reflecting the development of benign prostatic hyperplasia (BPH). 
Prostate growth is dependent on the presence of androgens, and conversely, anti-
androgen agents or orchidectomy can decrease prostate volume in patients with BPH. 
Thus, it is important to investigate whether ART could have any negative effects on 
prostatic disease or lower urinary tract symptoms (LUTS). Although only limited 
amounts of information on the correlations between androgen levels in aging men and 
clinical manifestations of LUTS are available, a few recent studies have suggested that 
testosterone levels may have some beneficial effects on various urinary functions in 
men. Androgen receptors are found in the urothelium, urinary bladder, prostate, and 
urethra, and testosterone could have an impact on the autonomic nervous system, blad-
der smooth muscle differentiation, nitric oxide synthase, phosphodiesterase-5 and 
Rho/Rho-kinase activities, and pelvic blood flow. In addition, some previous studies 
demonstrated that ART had little effect on LUTS or urinary function in aging men with 
LOH syndrome. Furthermore, some recent randomized controlled trials indicated that 
short-term ART may be effective in the improvement of LUTS in hypogonadal men with 
mild BPH. However, only limited information is available regarding the effects of lon-
ger-term ART or the safety of ART in men with severe BPH and LUTS, and further 
studies are required to reach more definitive conclusions.
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INTRODUCTION
Currently, the number of individuals over 65 years of age 
has increased more than 10-fold compared with the 1990s, 
and the number of elderly people will continue to increase 
worldwide in the future. In women, ovarian hormone pro-
duction decreases from about 50 years of age, which often 
results in various menopausal symptoms. Hormone re-
placement therapy can contribute to maintenance of qual-
ity of life in older women. On the other hand, biologically 
active free testosterone levels are known to decline with age 
by 2% to 3% annually in men, which may result in an-
dropause symptoms [1]. The clinical condition associated 
with low levels of serum testosterone with specific symp-
toms is called late-onset hypogonadism (LOH) syndrome. 
The Massachusetts Male Aging Study demonstrated that 
the prevalence of hypogonadism in men ranges from 6.0% 
to 12.3% between the ages of 40 and 69 years and estimated 
that 2.4 million men in the United States have androgen 
deficiency [2]. The widely recognized clinical signs of LOH 
syndrome are decreases in libido and sexual desire, de-
creases in muscle mass and strength, a decrease in bone 
mineral density, an increase in visceral fat, loss of memory, 
anemia, and deterioration of insulin resistance [3-5]. 
Furthermore, some studies indicated that low T levels are 
associated with increased risk for the development of type Korean J Urol 2011;52:657-663
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2 diabetes mellitus or cardiovascular disease [3,6,7]. 
Therefore, LOH syndrome is considered to be a clinical con-
dition that could affect the functions of multiple organ sys-
tems, and LOH syndrome itself is an important sign of 
many potentially serious conditions. Androgen replace-
ment therapy (ART) is a widely accepted form of treatment 
to prevent and ameliorate many of the symptoms and con-
ditions associated with LOH in aging men. According to 
practical industry estimates, more than 1.8 million pre-
scriptions for testosterone products were issued in the 
United States in 2002, representing a 30% increase over 
the previous 5 years [8].
On the other hand, there is a gradual increase in prostate 
volume concomitant with the progressive decline in testos-
terone from middle age, reflecting the evolution of benign 
prostatic hyperplasia (BPH), a common disease of later life 
affecting older men [9]. Several studies have shown the fre-
quency of lower urinary tract symptoms (LUTS) caused by 
BPH to be from 8% to 31% in men in their fifties, increasing 
to 27% to 44% of men in their seventies [10]. Prostate 
growth is dependent on the presence of androgens, and an-
drogens play an important role in the development of BPH. 
Conversely, administration of antiandrogen agents and or-
chidectomy can decrease prostate volume in patients with 
BPH [11]. These observations suggest that ART may poten-
tially worsen LUTS by increasing prostate volume, and po-
tential concerns regarding the effects of testosterone on 
prostate disease and LUTS must be addressed. Because 
LUTS is also associated with an increased risk of falls, di-
minished quality of life, depression, and sadness, similar 
to LOH syndrome [12], it is important to investigate the ef-
fects of hypogonadism or ART on prostatic disease and 
LUTS.
At present, little is known about the correlations be-
tween androgen levels in aging men and clinical manifes-
tations of LUTS [10]. Furthermore, there are no compelling 
data suggesting that ART contributes to exacerbation of 
LUTS or promotion of urinary retention [3]. Therefore, we 
reviewed the relationship between LOH syndrome and 
LUTS and the effects of ART on LUTS in hypogonadal men.
SERUM SEX HORMONES AND LOWER URINARY 
TRACT SYMPTOMS
Many studies have established the potential relationship 
between testosterone levels and erectile dysfunction (ED) 
or metabolic syndrome, whereas there have been few stud-
ies of the relationship between testosterone and LUTS [3]. 
There are several similarities in the etiologies of ED and 
LUTS, such as metabolic syndrome, autonomic nervous ac-
tivity, nitric oxide (NO) activity, arteriosclerosis, pelvic is-
chemia, and Rho-kinase activity [13]. Furthermore, recent 
studies suggested that BPH and LUTS are significantly as-
sociated with metabolic syndrome, and that patients with 
LUTS may share the same metabolic abnormalities as 
those with metabolic syndrome [14-16]. These findings 
suggest a relation between declines of testosterone and 
LUTS.
Several reports have been published regarding the rela-
tionships between various serum sex hormones and LUTS. 
Schatzl et al reported that hypogonadism was detected in 
22.1% of 312 men with LUTS but had no impact on 
International Prostate Symptom Score (IPSS), maximum 
flow rate (MFR), prostate volume, or prostate-specific anti-
gen (PSA) level [17]. One large population study indicated 
that circulating levels of sex hormones are generally not 
significant predictors of LUTS in men after adjustment for 
age, and the pathophysiology of LUTS is complex and prob-
ably includes factors other than circulating sex steroid lev-
els [18]. Also, no consistent correlations were shown be-
tween testosterone or free testosterone and LUTS in anoth-
er cross-sectional study [19]. 
On the other hand, some studies have indicated inverse 
associations between total testosterone, bioavailable tes-
tosterone, and free testosterone with LUTS. One pro-
spective study investigating serum sex hormones and the 
20-year risk of LUTS in 185 men with a mean age of 58 years 
revealed a significant inverse association between dihy-
drotestosterone and LUTS and indicated that men with 
higher concentrations of bioavailable testosterone had a 
56% decreased risk of LUTS compared with those with hy-
pogonadal concentrations. However, this study demon-
strated no relationship between total testosterone and 
LUTS [20]. Miwa et al noted that LUTS were not associated 
with serum levels of total testosterone and free testoster-
one, but storage symptom scores of the IPSS could be af-
fected by the serum dehydroepiandrosterone sulfate level 
in older men [21]. Furthermore, Tan et al reported that the 
decrease in serum free testosterone concentrations with a 
relative rise in serum estradiol levels with advancing age 
may be an important factor in the development of BPH in 
a population of 61 men aged 60 to 69 years [22]. These find-
ings indicated that the relationships between sex hormone 
levels and the development or severity of LUTS are conflict-
ing, and further studies in large populations of men with 
and without LUTS and with various severities of BPH are 
required to reach more definitive conclusions.
TESTOSTERONE LEVELS MAY AFFECT URINARY 
FUNCTION AND LOWER URINARY TRACT 
SYMPTOMS
As described above, the results of a few studies have sug-
gested that testosterone levels may have an effect on LUTS. 
Some interesting reports have also provided some insights 
into the mechanism of this effect (Fig. 1). 
Androgen receptors were found in the urothelium of the 
urinary bladder and urethra or autonomic neurons of pel-
vic ganglia in some experimental studies in rabbits and 
rats [23-25]. These neurons show remarkable sensitivity 
to androgens, and testosterone appears to play an im-
portant role in the morphology of pelvic autonomic neurons 
supplying the urinary bladder and urethra [26]. Indeed, 
one study demonstrated that castration decreased the Korean J Urol 2011;52:657-663
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FIG. 1. Hypotheses regarding the effects of testosterone level on 
lower urinary tract symptoms. The testosterone level is likely to 
have effects on the autonomic nervous system, Rho-kinase, and 
activities of nitric oxide (NO) synthase and phosphodiesterase-5 
(PDE5) through the androgen receptors localized on the lower 
urinary tract and may be associated with urinary functions. 
LOH: late-onset hypogonadism.
function of alpha 1-adrenergic and muscarinic cholinergic 
receptors in the urinary bladder, and testosterone replace-
ment restored these functions, indicating that testoster-
one has an effect on autonomic receptor function in the 
smooth muscle of the lower urinary tract [27]. Furthermore, 
androgen stimulates stromal precursor cells to differ-
entiate into smooth muscle cells. Cayan et al reported that 
in rats testosterone treatment resulted in a significantly 
higher bladder smooth muscle/collagen ratio than that in 
controls, suggesting that androgen interacts directly with 
the androgen receptors localized in the urinary bladder 
[28]. Madeiro et al also reported that the bladders of cas-
trated rats receiving androgen therapy for 28 days showed 
larger numbers of vessels, greater epithelial thickness, and 
larger quantities of muscular fibers than in untreated con-
trols [27]. 
The Rho and Rho-associated kinase pathway is also in-
volved in the autonomic system. Increased Rho-kinase ac-
tivity results in increased smooth muscle contraction, 
which leads to impaired erectile function and changes in 
bladder outlet tone [29]. Testosterone has been shown to 
have an effect on Rho-kinase activity, and Rho-kinase ac-
tivity in the urinary tract may be at least in part dependent 
on testosterone [10]. Rho-kinase plays a central role in the 
regulation of smooth muscle contraction of the urinary 
bladder and is associated with calcium sensitivity of the 
contractile machinery in prostate smooth muscle of BPH 
or in the detrusor of bladder outlet obstruction in ex-
perimental animal models [30]. Increased Rho-kinase ac-
tivity coincides with the development of LUTS in aging men 
with BPH, and inhibition of Rho-kinase in the rat model 
is considered to decrease prostatic smooth muscle cell pro-
liferation and to decrease adrenergic contractions [31]. 
As further substantiation of the relationship between 
testosterone levels and LUTS, testosterone regulates not 
only cyclic guanosine monophosphate formation through 
NO synthase stimulation but also its catabolism through 
phosphodiesterase-5 (PDE-5) activity. NO induces vaso-
dilation and is the basis for using PDE-5 in the treatment 
of erectile dysfunction. NO is also one of the mediators of 
dilatation of the urethra and bladder neck. NO synthase 
gene expression is reduced with aging in rat prostate tissue 
and may be a factor involved in the increased smooth mus-
cle tone associated with LUTS [30]. Chamness et al re-
ported that testosterone had an effect on NO synthase in 
the urinary tract and suggested the possibility of improv-
ing urinary symptoms by increasing NO production [32]. 
Moreover, the presence of PDE-5 was identified in the uri-
nary bladder [33], and PDE-5 appeared to regulate the 
smooth muscle tone of the bladder. Indeed, it has been clin-
ically demonstrated that PDE-5 inhibitors have a benefi-
cial effect on LUTS [34-36]. Alternatively, elevated testos-
terone levels or testosterone replacement also activate en-
dothelial NO synthase and consequently increase NO con-
centration in the tissue of the vessels, resulting in dilation 
of pelvic vessels and alleviation of pelvic ischemia. A de-
crease in bladder blood flow has been suggested in BPH pa-
tients [37], and decreased bladder blood flow and ischemia 
caused by aging and arterial sclerosis are associated with 
the development of detrusor overactivity and LUTS [38, 
39]. Chronic bladder ischemia is attributable to bladder 
distention induced by bladder outlet obstruction [40]. 
EFFECTS OF ANDROGEN REPLACEMENT ON 
LOWER URINARY TRACT SYMPTOMS
The relationships between ART and the risk of progression 
of BPH or LUTS have been discussed in the literature 
(Table 1). First, Franchi et al noted that oral testosterone 
undecanoate replacement for 8 months at doses from 40 to 
160 mg/day resulted in no subjective increase in prostate 
size or deterioration of voiding symptoms [41]. A place-
bo-controlled study using weekly injection of 100 mg of tes-
tosterone enanthate for 3 months did not significantly in-
crease prostate volume or postvoiding residual (PVR) vol-
ume [42]. Another double-blind controlled study demon-
strated that ART resulted in an increase of 12% in volume 
of the prostate gland after 8 months of treatment but did 
not affect uroflowmetry (UFM) data, PVR, or IPSS [43]. 
Behre et al reported a comparison of prostate volume meas-
ured by transrectal ultrasonography, serum levels of PSA 
and sex hormones, and UFM parameters in a controlled 
cross-sectional study [44]. There were no significant differ-
ences in UFM data between 78 hypogonadotropic hypo-
gonadism patients who received ART for ＞6 months, 75 
normal age-matched men, and 47 untreated hypogonado-
tropic hypogonadism patients. Furthermore, no signifi-
cant differences in prostate volume or PSA value were de-
tected between hypogonadism patients who received ART 
and normal controls. Marks et al reported an interesting 
double-blind placebo-controlled study and noted that 6 Korean J Urol 2011;52:657-663
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TABLE 1. The previous reports regarding the effects of androgen replacement therapy on lower urinary tract symptoms
Study Design N Treatment regimen Results Referece
Franchi (1978) CS 34 Oral T undecanoate (40-160 mg; 
daily for 8 months) 
ART had no subjective increase in prostate size 
or deterioration of voiding symptoms. 
41
Tenover (1992) RCT 13 IM T enanthate (100 mg; weekly for 
3 months) vs placebo
There were not significant increase in prostate 
volume or PVR, and a sustained increase in 
serum PSA levels.
42
Holmäng (1993) RCT 23 Oral T undecanoate (160 mg; daily 
for 8 months) vs placebo
ART resulted in an increase of 12% in volume 
of the prostate gland after 8 months of 
treatment, but did not affect UFM data, PVR.
43
Gooren (1994) CS 33 Oral T undecanoate (80-200 mg; 
daily for 10 years)
Urine flow showed a slight decrease, but no 
increase was shown in prostate size.
50
Behre (1994) CS Group 1 (N=47)
Group 2 (N=78)
Group 3 (N=75)
Group 1: untreated hypogonadotropic 
hypogonadism
Group 2: ART-received patients
Group 3: age-matched normal 
controls 
There was no significant difference in UFM 
data of the three groups. Furthermore, no 
significant difference was detected in PSA 
value and prostate volume between ART 
group and normal age-matched controls.
44
Sih (1997) RCT 32 T cypionate (200 mg; biweekly for 12 
months) vs placebo
There were not significant increase in PSA, and 
no patients who had worsening of urinary 
symptoms.
46
Kenny (2001) RCT 67 Transdermal T patch (5 mg; daily for 
one year) vs placebo
 Testosterone resulted in a modest increase 
(not significantly) in PSA levels but resulted 
in no change in signs or symptoms of prostate 
hyperplasia
47
Perchersky 
  (2002)
DRS 207 Oral T undecanoate (80-120 mg; 
daily for 6 months)
ART resulted in a decrease of approximately 
30% in prostate volume and a significant 
decrease of IPSS score
51
Marks (2006) RCT 44 IM T enanthate (150 mg; biweekly 
for 6 months) vs placebo
ART had little effect on prostatic tissue 
androgen levels, such as those of testosterone 
and DHT, or on their urinary symptoms and 
UFM data.
45
Saad (2008) DRS Group 1 (N=28)
Group 2 (N=27)
Group 1: IM T undecanoate 
(1,000 mg for 9 months) 
Group 2: T gel (50 mg; daily for 9 monts)
Plasma PSA values remained stable for 9 
months wit both T gel and T undecanoate, 
whereas the scores on the IPSS improved 
slightly (not significantly) in both groups.
48
Karazindi-
  yanoğlu (2008)
CS 25 T gel (50-100 mg; daily for one year) ART contributed to a significant increase in 
prostate volume, but had an improvement in 
IPSS score. ART significantly increased 
maximal bladder capacity and compliance, 
and decreased detrusor pressure at maximal 
flow based on PFS.
52
Kalinchenko 
(2008)
DRS Group 1 (N=10)
Group 2 (N=20)
Group 1: T gel (50 mg; daily for 26 
weeks)
Group 2: IM T undecanoate (1000 mg 
for 26 weeks)
ART improved total IPSS score, irriative 
symptoms, obstructive symptoms, and 
nocturia. But total PSA value did not change 
significantly.
53
Takao (2009) CS 21 T enanthate (125 mg; triweekly for 3 
monts) or hCG (5000 IU for 3 months)
ART had no short-term effects on IPSS and 
QOL-index.
49
Amano (2010) CS 41 Glowmin (6 mg; daily for 3 months) ART was effective in the improvement of IPSS 
and its subscores.
54
Shigehara 
(2011)
RCT 46 (ART: 23, 
Control 23)
IM T enanthate (250 mg; monthly for 
12 months)
ART for the patients with LOH and mild BPH 
had improvement in IPSS score, MFR and VV, 
but had no effects on PVR and PSA. 
55
RCT: romdomized controlled study, CS: case series, DRS: dose-response study, IM: intramuscular, T: testosterone, ART: androgen 
replacement therapy, PVR: post-voiding residual volume, PSA: prostate specific antigen, UFM: uroflowmetry, IPSS: international pros-
tate symptom score, DHT: dihydrotestosterone, PFS: pressure flow study, BPH: benign prostate hyperplasia, QOL: quality of life, MFR: 
maximum flow rate, VV: voided volumeKorean J Urol 2011;52:657-663
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months of testosterone administration normalized serum 
androgen levels in aging men with hypogonadism but had 
little effect on prostatic tissue androgen levels, such as 
those of testosterone and dihydrotestosterone, or on the pa-
tients’ urinary symptoms and UFM data [45]. Furthermore, 
no ART-related changes were observed in prostate histol-
ogy or tissue biomarkers, such as androgen receptor, Ki-67, 
and CD34, in the biopsy samples. Other studies demon-
strated many beneficial systemic effects of ART but failed 
to show a significant exacerbation of LUTS during ART, 
and complications, such as urinary retention, did not occur 
at higher rates than in controls [46-49]. These studies have 
demonstrated that ART for a short period of within 1 year 
has little negative effect on urinary function or prostate 
volume.
On the other hand, a long-term clinical study using oral 
testosterone undecanoate for 10 years in 33 men demon-
strated a slight decrease in urine flow but no increase in 
prostate size and no evidence of cancer development [50]. 
However, there have been few studies including pop-
ulations with long-term observation of ART and with se-
vere BPH or LUTS. Clearly, further long-term observa-
tional trials including patients with varying severities of 
BPH are required to clarify the possible effects of ART on 
the prostate or LUTS due to BPH.
ANDROGEN REPLACEMENT CAN CONTRIBUTE 
TO IMPROVEMENT OF LOWER URINARY TRACT 
SYMPTOMS IN HYPOGONADAL MEN
As described above, the potential relationship between 
LUTS and LOH syndrome has been addressed, and some 
recent studies also demonstrated that ART improved 
LUTS in hypogonadal men (Table 1). An uncontrolled 
study indicated progressive reduction of prostate volume 
and improvement of urinary symptoms among 207 mid-
dle-aged and older men who were treated with oral testos-
terone undecanoate at a dose of 80 to 120 mg daily for 6 
months [51]. This previous report indicated that ART re-
sulted in a decrease of approximately 30% in prostate vol-
ume and a significant decrease in IPSS. On the other hand, 
they also reported that 20 patients had no suppression of 
plasma luteinizing hormone, which reflects defects in hy-
pothalamic-pituitary regulation in testicular function, 
suggesting failure to demonstrate a consistent increase in 
plasma testosterone level, and did not show a decrease in 
prostate volume. These findings suggest that successful 
ART could improve urinary symptoms and BPH directly. 
Karazindiyanoğlu et al mentioned that ART with trans-
dermal testosterone gel (50 to 100 mg) per day for 1 year 
in 25 men with LOH syndrome improved the IPSS, al-
though mean prostate volume showed a significant in-
crease [52]. Furthermore, according to the results of pres-
sure-flow analysis, this study demonstrated that ART sig-
nificantly increased maximal bladder capacity and com-
pliance and decreased detrusor pressure at maximal flow. 
Kalinchenko et al also reported that two types of testoster-
one administration (testosterone gel or testosterone un-
decanoate) improved many LUTS, such as irritative symp-
toms, obstructive symptoms, and nocturia, in men with 
LOH syndrome [53]. Amano et al noted that ART by admin-
istration of testosterone ointment (Glowmin) 6 mg/day for 
3 months contributed to elevation of serum testosterone 
levels observed within the normal range and was effective 
in improving not only ED and LOH symptoms but also 
LUTS (especially voiding disturbance) in 41 patients with 
LOH [54]. 
Recently, we reported a randomized controlled study re-
garding the effects of ART on LUTS in 52 hypogonadal men 
with mild BPH [55]. Fifty-two patients were randomly as-
signed to receive testosterone (ART group 26 patients) as 
250 mg of testosterone enanthate every 4 weeks or to the 
untreated control group (26 patients), and IPSS, UFM da-
ta, and PVR at baseline and 12 months after treatment 
were compared. Finally, 46 patients (ART group, n=23; 
control group, n=23) who completed this trial over 12 
months were included in the analysis. At the 12-month vis-
it, IPSS showed a significant decrease compared with base-
line in the ART group (15.7±8.7 vs. 12.5±9.5; p＜0.05), 
whereas no significant changes were observed in the con-
trol group (14.0±10.1 vs. 13.5±9.8; p=0.345). The ART 
group also showed improvement in MFR (from 12.9±5.6 to 
16.7±9.5 ml/s, p＜0.05) and voided volume (VV: from 
253±120 to 283±145 ml/s, p＜0.05), whereas no significant 
improvements were observed in the controls. Further-
more, IPSS subscores showed improvements in categories 
associated with MFR (Q5: “Over the past month, how often 
have you had a weak urinary stream?”) and VV (Q2: “Over 
the past month, how often have you had to urinate again 
less than two hours after you finished urinating?”) in the 
ART group. PVR showed no significant changes in either 
group. This was the first randomized controlled study sug-
gesting that ART may improve LUTS in hypogonadal men 
with mild BPH by increasing MFR and VV. During this 
study period, there were no patients who required prostate 
biopsy or had a diagnosis of prostate cancer. With regard 
to the safety of ART for 1 year, no other severe adverse 
events occurred that resulted in withdrawal from the trial. 
Urinary complications, such as severe exacerbation of 
voiding symptoms or urinary retention, did not occur in ei-
ther group. Furthermore, no patients required additional 
medication or changed drugs because of worsening urinary 
symptoms during the period of this trial. However, the limi-
tations of the present study included the small sample size 
and the lack of data based on urodynamic study. Moreover, 
the severity of BPH in the target population was mild, and 
the present results may not necessarily be applicable to pa-
tients with severe BPH. Therefore, further studies includ-
ing long-term observations and many patients with severe 
BPH or LUTS are required to reach more definitive con-
clusions regarding the associations between testosterone 
therapy and urinary function.Korean J Urol 2011;52:657-663
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CONCLUSIONS
Many previous studies have demonstrated that ART has 
few negative effects on urinary function, LUTS, or prostate 
volume among aging men for at least about 1 year. There 
are many benefits of ART for hypogonadal aging men re-
garding many general conditions, such as loss of muscle 
mass and strength, bone mineral density, enhanced memo-
ry, sexual function, insulin resistance, improvement of 
metabolic syndrome and visceral fat, and general sense of 
well-being. As an additional benefit, ART may also be effec-
tive for improving LUTS in aging men. However, currently, 
ART is generally a relative contraindication in severe BPH 
and LUTS with an IPSS of more than 19. Furthermore, only 
limited information is available regarding the effects of 
ART in men for longer periods, and further studies includ-
ing long-term observations and many patients with vary-
ing severities of BPH or LUTS are required to reach more 
definitive conclusions.
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